Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;19(Suppl 1):S67-70.

Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran

Bahareh Vakili  1 , Hossein Fazeli  2 , Parisa Shoaei  3 , Majid Yaran  4 , Behrooz Ataei  2 , Farzin Khorvash  3 , Moj Khaleghi  5
Affiliations

Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran

Bahareh Vakili et al. J Res Med Sci. 2014 Mar.

Abstract

Background: Nosocomial infection caused by Acinetobacter baumannii has emerged as a serious problem world-wide. Finding the suitable drug is an important priority. The aim of this study was to determine colistin (polymyxin E) resistance in clinical isolates of A. baumannii from intensive care units (ICUs) of Al Zahra Hospital.

Materials and methods: Sixty isolates of A. baumannii from patients hospitalized in ICU (Al Zahra Hospital, Isfahan University of Medical Sciences [IUMS]) were studied. All isolates of A. baumannii were tested for colistin susceptibility by Eopsilometer test (E-test).

Results: Of the 60 isolates 57, (95%) were multidrug resistant (MDR) and 76.6% (46/60) were highly resistant. The rate of colistin resistant with the E-test method was 11.6% (7/60).

Conclusion: As the frequency of resistance to colistin is low, it can be used as an easily available drug for treatment of MDR A. baumannii strains, which are susceptible to colistin.

Keywords: Acinetobacter baumannii; colistin resistance; multidrug resistant organism.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflict of interest.

Figures

Figure 1
Figure 1
Antimicrobial resistance rates among Acinetobacte baumannii isolates. GM = Gentamicin, CIP = Ciprofloxacin, AK = Amikacin, FEP = Cefepime, CAZ = Ceftazidime, TZP = Piperacillin/tazobactam, SAM = Ampicillin/sulbactam, MER = Meropenem, IMP = Imipene
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ducel G, Fabry J, Nicolle L, Girard R, Perraud M, Prüss A, et al. Prevention of hospital-acquired infections. [Last accessed on 2013 Dec 11]. Available from: http://www.who.int/emc .
    1. Arroyo LA, García-Curiel A, Pachón-Ibañez ME, Llanos AC, Ruiz M, Pachón J, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005;43:903–5. - PMC - PubMed
    1. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: Citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31:101–6. - PubMed
    1. Chien ST, Lin CH, Hsueh JC, Li PL, Hsu CH, Chang SH, et al. Mutation of gyrA and parC in clinical isolates of Acinetobacter baumannii and its relationship with antimicrobial drugs resistance in Taiwan. Ann Microbiol. 2009;59:369–72.
    1. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:1163–7. - PubMed